Prelude Therapeutics Stock Analysis
| PRLD Stock | USD 0.70 0.02 2.78% |
Prelude Therapeutics is overvalued with Real Value of 0.69 and Target Price of 5.0. The main objective of Prelude Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Prelude Therapeutics is worth, separate from its market price. There are two main types of Prelude Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Prelude Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Prelude Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Prelude |
Prelude Stock Analysis Notes
About 69.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.3. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Prelude Therapeutics recorded a loss per share of 1.68. The entity had not issued any dividends in recent years. Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware. Prelude Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 112 people. To find out more about Prelude Therapeutics contact Krishna DVM at 302 467 1280 or learn more at https://preludetx.com.Prelude Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Prelude Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Prelude Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Prelude Therapeutics generated a negative expected return over the last 90 days | |
| Prelude Therapeutics has high historical volatility and very poor performance | |
| Prelude Therapeutics has some characteristics of a very speculative penny stock | |
| Prelude Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7 M. Net Loss for the year was (127.17 M) with profit before overhead, payroll, taxes, and interest of 7 M. | |
| Prelude Therapeutics currently holds about 246.3 M in cash with (102.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 69.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Vaddi Krishna of 15000 shares of Prelude Therapeutics at 0.7306 subject to Rule 16b-3 |
Prelude Therapeutics Upcoming and Recent Events
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Prelude Largest EPS Surprises
Earnings surprises can significantly impact Prelude Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-05-11 | 2021-03-31 | -0.42 | -0.47 | -0.05 | 11 | ||
2024-05-07 | 2024-03-31 | -0.48 | -0.42 | 0.06 | 12 | ||
2023-08-03 | 2023-06-30 | -0.63 | -0.54 | 0.09 | 14 |
Prelude Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 402.3 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 392.2 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 365.2 K | Two Sigma Advisers, Llc | 2024-12-31 | 300 K | State Street Corp | 2024-12-31 | 293.4 K | Two Sigma Investments Llc | 2024-12-31 | 231.8 K | Rhumbline Advisers | 2024-12-31 | 166.8 K | Td Asset Management Inc | 2024-12-31 | 160.7 K | Goldman Sachs Group Inc | 2024-12-31 | 148.3 K | Orbimed Advisors, Llc | 2024-12-31 | 10.9 M | Baker Bros Advisors Lp | 2024-12-31 | 10.1 M |
Prelude Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 39.71 M.Prelude Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.72) | (0.76) | |
| Return On Capital Employed | (0.93) | (0.98) | |
| Return On Assets | (0.72) | (0.76) | |
| Return On Equity | (0.97) | (0.92) |
Management Efficiency
Prelude Therapeutics has return on total asset (ROA) of (0.3854) % which means that it has lost $0.3854 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6901) %, meaning that it created substantial loss on money invested by shareholders. Prelude Therapeutics' management efficiency ratios could be used to measure how well Prelude Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 25, 2025, Return On Tangible Assets is expected to decline to -0.76. In addition to that, Return On Capital Employed is expected to decline to -0.98. At present, Prelude Therapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 177.2 M, whereas Non Currrent Assets Other are forecasted to decline to about 3.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.73 | 2.10 | |
| Tangible Book Value Per Share | 1.73 | 2.10 | |
| Enterprise Value Over EBITDA | (0.73) | (0.77) | |
| Price Book Value Ratio | 0.73 | 0.77 | |
| Enterprise Value Multiple | (0.73) | (0.77) | |
| Price Fair Value | 0.73 | 0.77 | |
| Enterprise Value | 101.8 M | 96.7 M |
The decision-making processes within Prelude Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Technical Drivers
As of the 25th of March, Prelude Therapeutics holds the Variance of 68.87, coefficient of variation of (23,189), and Risk Adjusted Performance of 0.005. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Prelude Therapeutics, as well as the relationship between them. Please check Prelude Therapeutics coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and skewness to decide if Prelude Therapeutics is priced some-what accurately, providing market reflects its current price of 0.7 per share. As Prelude Therapeutics is a penny stock we also suggest to check out its jensen alpha numbers.Prelude Therapeutics Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Prelude Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Prelude Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Prelude Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Prelude Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Prelude Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Prelude Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Prelude Therapeutics Outstanding Bonds
Prelude Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Prelude Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Prelude bonds can be classified according to their maturity, which is the date when Prelude Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Prelude Therapeutics Predictive Daily Indicators
Prelude Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Prelude Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 0.7 | |||
| Day Typical Price | 0.7 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.02) | |||
| Relative Strength Index | 41.92 |
Prelude Therapeutics Forecast Models
Prelude Therapeutics' time-series forecasting models are one of many Prelude Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Prelude Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Prelude Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Prelude Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Prelude shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Prelude Therapeutics. By using and applying Prelude Stock analysis, traders can create a robust methodology for identifying Prelude entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (16.35) | (17.17) | |
| Operating Profit Margin | (17.96) | (18.86) | |
| Net Loss | (16.35) | (17.17) |
Current Prelude Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Prelude analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Prelude analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 5.0 | Buy | 5 | Odds |
Most Prelude analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Prelude stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Prelude Therapeutics, talking to its executives and customers, or listening to Prelude conference calls.
Prelude Stock Analysis Indicators
Prelude Therapeutics stock analysis indicators help investors evaluate how Prelude Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Prelude Therapeutics shares will generate the highest return on investment. By understating and applying Prelude Therapeutics stock analysis, traders can identify Prelude Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 29.3 M | |
| Common Stock Shares Outstanding | 75.8 M | |
| Total Stockholder Equity | 131.5 M | |
| Property Plant And Equipment Net | 35.5 M | |
| Cash And Short Term Investments | 133.6 M | |
| Cash | 12.5 M | |
| Accounts Payable | 7.7 M | |
| Net Debt | 5.6 M | |
| 50 Day M A | 0.9211 | |
| Total Current Liabilities | 25.6 M | |
| Other Operating Expenses | 146.7 M | |
| Non Current Assets Total | 39.6 M | |
| Non Currrent Assets Other | 4.2 M | |
| Stock Based Compensation | 21.3 M |
Complementary Tools for Prelude Stock analysis
When running Prelude Therapeutics' price analysis, check to measure Prelude Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prelude Therapeutics is operating at the current time. Most of Prelude Therapeutics' value examination focuses on studying past and present price action to predict the probability of Prelude Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prelude Therapeutics' price. Additionally, you may evaluate how the addition of Prelude Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |